Key result
Combinations of angiotensin II receptor blockers were associated with a 30% lower t-tau/Aß42 ratio compared to plain angiotensin-converting enzyme inhibitors.
Why the study?
The role of antihypertensive medications in Alzheimer disease prevention is controversial.
Do angiotensin II receptor blockers reduce the tau/Aß42 ratio compared to ACE inhibitors in patients with or without Alzheimer's Disease?
Population
Patients with AD diagnosis vs cognitively healthy controls
Comparison
Prescribed antihypertensive drugs
Design
Case-control study
Authors
Loading...
Should not alter antihypertensive choices; hypothesis-generating for ARB effects on Alzheimer's biomarkers.
Case-Control
Do angiotensin II receptor blockers reduce the tau/Aß42 ratio compared to ACE inhibitors in patients with or without Alzheimer's Disease?
Effect estimate: 30% lower
Angiotensin II receptor blockers may offer neuroprotective benefits by reducing pathological tau and amyloid ratios compared to ACE inhibitors.
García‐Lluch et al. (2023) conducted a case-control in Alzheimer's Disease. Angiotensin II receptor blockers vs. Angiotensin-converting enzyme inhibitors was evaluated on t-tau/Aß42 ratio (30% lower). Combinations of angiotensin II receptor blockers were associated with a 30% lower t-tau/Aß42 ratio compared to plain angiotensin-converting enzyme inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: